Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Sep;26(9):2347-53.
doi: 10.1007/s00198-015-3129-7. Epub 2015 Jun 20.

Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX

N C Harvey  1 , J A Kanis, A Odén, T Nakamura, M Shiraki, T Sugimoto, T Kuroda, H Johansson, E V McCloskey
Affiliations
Clinical Trial

Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX

N C Harvey et al. Osteoporos Int. 2015 Sep.

Abstract

The aim of this study was to determine the efficacy of once-weekly teriparatide as a function of baseline fracture risk. Treatment with once-weekly teriparatide was associated with a statistically significant 79 % decrease in vertebral fractures, and in the cohort as a whole, efficacy was not related to baseline fracture risk.

Introduction: Previous studies have suggested that the efficacy of some interventions may be greater in the segment of the population at highest fracture risk as assessed by the FRAX® algorithms. The aim of the present study was to determine whether the antifracture efficacy of weekly teriparatide was dependent on the magnitude of fracture risk.

Methods: Baseline fracture probabilities (using FRAX) were computed from the primary data of a phase 3 study (TOWER) of the effects of weekly teriparatide in 542 men and postmenopausal women with osteoporosis. The outcome variable comprised morphometric vertebral fractures. Interactions between fracture probability and efficacy were explored by Poisson regression.

Results: The 10-year probability of major osteoporotic fractures (without BMD) ranged from 7.2 to 42.2 %. FRAX-based hip fracture probabilities ranged from 0.9 to 29.3 %. Treatment with teriparatide was associated with a 79 % (95 % CI 52-91 %) decrease in vertebral fractures assessed by semiquantitative morphometry. Relative risk reductions for the effect of teriparatide on the fracture outcome did not change significantly across the range of fracture probabilities (p = 0.28). In a subgroup analysis of 346 (64 %) participants who had FRAX probabilities calculated with the inclusion of BMD, there was a small but significant interaction (p = 0.028) between efficacy and baseline fracture probability such that high fracture probabilities were associated with lower efficacy.

Conclusion: Weekly teriparatide significantly decreased the risk of morphometric vertebral fractures in men and postmenopausal women with osteoporosis. Overall, the efficacy of teriparatide was not dependent on the level of fracture risk assessed by FRAX in the cohort as a whole.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Hazard ratio between treatments (teriparatide versus placebo) for morphometric vertebral fractures according to the 10-year probability of a major osteoporotic fracture calculated without inclusion of BMD (HR presented from 10th to 90th percentile). Note that greater HR implies lower efficacy
See this image and copyright information in PMC

References

    1. Reeve J, Meunier PJ, Parsons JA, et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J. 1980;280:1340–1344. doi: 10.1136/bmj.280.6228.1340. - DOI - PMC - PubMed
    1. Devogelaer JP, Boutsen Y, Manicourt DH. Biologicals in osteoporosis: teriparatide and parathyroid hormone in women and men. Curr Osteoporos Rep. 2010;8:154–161. doi: 10.1007/s11914-010-0024-1. - DOI - PubMed
    1. Resmini G, Iolascon G. New insights into the role of teriparatide. Aging Clin Exp Res. 2011;23(2 Suppl):30–32. - PubMed
    1. Kanis JA McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y, on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24:23–57. doi: 10.1007/s00198-012-2074-y. - DOI - PMC - PubMed
    1. Vescini F, Grimaldi F. PTH 1-84: bone rebuilding as a target for the therapy of severe osteoporosis. Clin Cases Miner Bone Metab. 2012;9:31–36. - PMC - PubMed

Publication types

MeSH terms

Substances